NCT03512353 · OUTCOME

Percentage of Participants With PFS Events by Prior Lines of Therapy

A Study of Carfilzomib Plus Dexamethasone in Adults With Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers · Source last updated 2021-01-08

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: percentage of participants
Interval / dispersion: Not reported
Time frame: Disease assessments were performed every 28 days up to 12 months from enrollment.

What was measured

Progression-free survival (PFS) events include disease progression or death due to any cause. Disease progression was determined by the Investigator according to IMWG criteria.

Analysis population: All enrolled and treated participants

Groups in this outcome

1 Prior Line of Therapy

Participants with 1 prior line of therapy for multiple myeloma.

2+ Prior Lines of Therapy

Participants with ≥ 2 prior lines of therapy for multiple myeloma.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
1 Prior Line of Therapy	4
2+ Prior Lines of Therapy	2

Reported measurements

Source class 1

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1 Prior Line of Therapy	50.0	Not reported	Not reported	Not reported	Not reported
2+ Prior Lines of Therapy	50.0	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
50.0
group Id
OG001
value
50.0

denoms

counts
group Id
OG000
value
4
group Id
OG001
value
2
units
Participants

description

Progression-free survival (PFS) events include disease progression or death due to any cause. Disease progression was determined by the Investigator according to IMWG criteria.

groups

description
Participants with 1 prior line of therapy for multiple myeloma.
id
OG000
title
1 Prior Line of Therapy
description
Participants with ≥ 2 prior lines of therapy for multiple myeloma.
id
OG001
title
2+ Prior Lines of Therapy

param Type

NUMBER

population Description

All enrolled and treated participants

reporting Status

POSTED

time Frame

Disease assessments were performed every 28 days up to 12 months from enrollment.

title

Percentage of Participants With PFS Events by Prior Lines of Therapy

type

SECONDARY

unit Of Measure

percentage of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice